Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
CMML is a stem cell disorder with heterogeneous clinical and pathologic features, often sharing characteristics of both myelodysplastic and myeloproliferative disorders. This study of 235 individuals registered in a German MDS Registry determined prognostic findings associated with overall survival and transformation to acute myeloid leukemia, specific to CMML. The authors identified 4 factors that were able to differentiate patients into 3 risk categories with expectant median survivals ranging from 11 months to 93 months. An alternative scoring system (from the Spanish Registry) is an option when cytogenetic studies are available.
References
Such E, Cervera J, Nomdedeu B, Pedro C, Bueno J, al. e. A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia. American Society of Hematology. New Orleans: Blood; 2009:abstract # 1750.
Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52-59.
View Abstract
CMML CPSS-Mol
Estimate risk of progression to AML in those with CMML using molecular genetics data
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email [email protected]